

























































Discovery of a Lead Brain-Penetrating Gonadotropin-
Releasing Hormone Receptor Antagonist with Saturable
Binding in Brain
Roberto B. W. Bekker,[a] Richard Fjellaksel,[b, c, d] Trine Hjornevik,[e] Syed Nuruddin,[f]
Waqas Rafique,[a] Jørn H. Hansen,[d] Rune Sundset,[b, c] Ira H. Haraldsen,[g] and
Patrick J. Riss*[a, f, g]
We report the synthesis, radiosynthesis and biological charac-
terisation of two gonadotropin-releasing hormone receptor
(GnRH  R) antagonists with nanomolar binding affinity. A small
library of GnRH  R antagonists was synthesised in 20–67%
overall yield with the aim of identifying a high-affinity
antagonist capable of crossing the blood–brain barrier. Binding
affinity to rat GnRH  R was determined by autoradiography in
competitive-binding studies against [125I]buserelin, and inhib-
ition constants were calculated by using the Cheng–Prusoff
equation. The radioligands were obtained in 46–79% radio-
chemical yield and >95% purity and with a molar activity of
19–38 MBq/nmol by direct nucleophilic radiofluorination. Posi-
tron emission tomography imaging in rat under baseline
conditions in comparison to pretreatment with a receptor-
saturating dose of GnRH antagonist revealed saturable uptake
(0.1%ID/mL) into the brain.
Our attention has been drawn towards the gonadotropin
releasing hormone receptor (GnRH  R) because of its role in
hormone related behaviour and in the pathophysiology of
several diseases. Gonadotropin releasing hormone is a decapep-
tide hormone (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2)
and a key neurotransmitter in the hypothalamus-pituitary-
gonadal axis. Apart from the classical role in reproduction,
GnRH plays a role in cell proliferation,[1,2] tumour progression,[3–5]
metastasis[4] and angiogenesis,[5] and has been linked to neuro-
degenerative cascades, for example, in dementia through
nonclassical mechanisms.[6–8] In circulation, the peptide acts as
an endocrine signalling hormone that mediates the release of
follicle stimulating hormone and luteinising hormone by
GnRH  R activation in the pituitary gland and other regions.[2,5–8]
As such, hormonal signalling cascades following GnRH  R
activation might catalyse the multiple actions of GnRH and
mediate hormone signalling in the central nervous system
(CNS). The GnRH  R is widely expressed in CNS; highester levels
are found in the olfactory bulb, hypothalamus, and
hippocampus.[5,7–9] Furthermore, GnRH  R plays an established
role in clinical care, for example, in the treatment of hormone-
responsive cancers, reproductive disorders and for behavioural
modification of sexual offenders through these mechanisms.
Recent observations also demonstrate crosstalk between
GnRH  R and growth factor receptors.[1–6]
Few publications have investigated GnRH  R antagonists for
PET. However, the role GnRH plays in pathophysiology of
diseases emphasises the potential of GnRH  R PET imaging.
In this study our main goal was to develop a PET imaging
probe for GnRH  R in brain.[16–18] In more detail, we were
interested in the development of a moderate-strength GnRH  R
antagonist to target brain imaging of GnRH  R as means to
detect and characterise brain cancer, both primary tumours and
metastases, as well as to elucidate CNS mechanisms of
behaviour, brain damage and cognition involving GnRH  R.[9–11]
In our reasoning, a reversibly binding antagonist of GnRH  R
would be particularly interesting because of its lack of receptor
stimulatory side effects and superior passive tissue permeability
to peptide agonists.[12]
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Several classes of small-molecular antagonist have been
investigated for imaging GnRH  R, and tested for positron
emission tomography (PET) imaging in the brain, however,
without success.[13–14] The authors point out several reasons for
failure such as affinity, molecular size and association kinetics.
We have pursued a library of GnRH  R antagonists that
addresses the moderate to high-affinity range allowing com-
petition of the ligand in circulation with endogenous GnRH at
GnRH  R binding sites. While the use of moderate affinity
antagonists may permit assessment of the receptor availability,
a measure reflecting both ligand concentration and the
concentration of the receptor in tissues, high-affinity ligands
may be required to image low concentration targets. Elagolix
(1) and relugolix (2) are potent small-molecule GnRH antago-
nists from a novel class drugs unrelated to the earlier peptide-
based ligands (Scheme 1). Given the pharmacokinetic profiles of
these approved drugs, we were certain that 1 and 2 would not
suffer from metabolic instability. At the same time, the high
lipophilicity (log D7.4) of 4 and 4.6, respectively, held promise of
decent brain uptake. Based on these considerations and
previous work wherein structure–activity relationships, affinity
and off target binding were assessed, we selected benzimida-
zol-derivative 3 and elagolix analogue 4, for further study.[12,15–18]
The primary objective in developing GnRH  R radiotracers for
brain imaging is achieving brain uptake and saturable binding
in brain, which has been elusive so far.
Reference 3 and the corresponding labelling precursor 5
were obtained by copper-mediated azide-alkyne cycloaddition
as described previously; however, 1.05 equiv. Cu was required
to achieve useful conversion of the starting material.[13]
Compound 6 was prepared by cyclisation of elagolix using bis
2-methylprop-2-yl pyrocarbonate in MeCN in a yield of 92% (a).
Demethylation was achieved using boron tribromide in di-
chloromethane furnish compound 7 in 64% yield (b). Com-
pound 7 was converted into the reference compound 4 ((R)-5-
(2-fluoro-3-(2-fluoroeth-1-oxy)phenyl)-1-(2-fluoro-6-
Scheme 1. Competitive binding affinities (Ki) for compounds 1–4 and synthetic route for radiolabelling compounds [
18F]3 and [18F]4: a) BOC2O, DMAP, MeCN,
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phenylethyl)pyrimidine-2,4(1H,3H)-dione) by using 2-fluoro eth-
1-yl 4-methylbenzenesulfonate dissolved in anhydrous MeCN




phenoxy)ethyl 4-methylbenzene sulfonate (8) was obtained in a
yield of 64% by treating 7 with an excess of ethylene ditosylate
in MeCN (d). The purity of each compound was determined by
reversed-phase HPLC prior to testing of the compounds’ bind-
ing affinity.
Competition binding experiments were conducted on flash-
frozen transversal brain sections (rat, 20 μm thickness), thaw
mounted on microscope slides. Following optimisation of times,
temperatures and radioligand concentration, experiments were
conducted with [125I]buserelin (AM=81.4MBq/nmol) at 22 °C.
Sections were incubated in assay buffer for 90 minutes in
presence of [125I]buserelin (0.6 nM) using eleven different
concentrations of test compounds in four separate experiments.
Nonspecific binding was determined using buserelin.[19,20] A BAS
MS imaging screen was exposed to the activity-loaded sections
for 2 weeks. The screen was then analysed with a Duerr
phosphor imager and [125I]Buserelin radioactivity in hippo-
campus was determined to obtain IC50 values using ray-test
AIDA image analysis software. IC50 values were obtained from
nonlinear curve fitting of the values obtained in individual
experiments and Ki values were calculated (Table 1).
[21]
In order to test the brain uptake of the lead compounds,
radiosynthesis conditions for production and formulation of
[18F]3 and [18F]4 were developed. Here, DMSO proved useful for
labelling, but spoiled the use of simple HPLC conditions. DMF
gave low yield unless heated to high temperature at which
point the molar activity of the product became unacceptably
low. MeCN was a charm to work with for purification, however,
it had to be heated beyond its boiling point in tightly capped
vials to achieve high conversion of [18F]fluoride ion within 10
minutes. After some optimisation, both compounds were
produced using 3 mg of precursors 5 and 8, respectively, for
direct, aliphatic nucleophilic radiofluorination in acetonitrile at
90 °C for 10 minutes.[18]
Under these conditions, [18F]3 was formed in a radio-
chemical yield of 46�2% and [18F]4 was formed in a radio-
chemical yield of 79�1%. At the end of the labelling reaction,
the reaction mixtures were diluted with MeCN/H2O (1 :1,
0.7 mL) and injected into a preparative HPLC system to purify
the labelled product. Radiotracer [18F]3 was purified on a Merck
Chromolith RP18 column (150×10 mm) using MeOH-
Ammonium formate (0.1 M, pH 7); 1 :1 as mobile phase at a
flow rate of 8.5 mL/min. The HPLC fraction containing the
product was collected 7–9 min after the injection. The product
fraction was diluted and [18F]3 was extracted using a waters
SepPak plus C18 cartridge pre-rinsed with EtOH and water. The
cartridge was washed with H2O (10 mL) afterwards and the
retained product was eluted into a clean glass vial with
endotoxin free physiological saline (0.9% NaCl) using EtOH (<
10%). The tracer was obtained in a nondecay corrected activity
yield of 11% (380 MBq) with a molar activity of 18.5 MBq/nmol
at delivery to the scanner. Candidate [18F]4 was purified on a
Supelco HS  F5 column (250×10 mm) with MeCN/water (55 :45)
as mobile phase at a flow rate of 5 mL/min.
The HPLC fraction containing the product was collected
(tR=11–12 min) in a round bottomed flask, diluted with water
(50 mL) and extracted via solid phase extraction (Phenomenex
Strata X C18) pre-rinsed with EtOH and water. The cartridge was
washed with H2O (10 mL) afterwards and the retained product
was eluted into a clean glass vial with endotoxin free
physiological saline (0.9% NaCl) using EtOH (<10%) in an
activity yield of 52% (uncorrected; 1.38 GBq) and a molar
activity of 38 MBq/nmol. The QC samples were analysed while
the radiotracers were shipped to the imaging facility. Both
radiotracers had a radiochemical purity >95% at the time of
injection.[22]
Animal experiments were conducted in accordance with
national Norwegian regulations on the use of laboratory
animals in research (FOR-2015-06-18-761), decision regarding
the use of animals in procedures - FOTS ID 12701, establish-
ment number 016: UiO–Institutt for medisinske basalfag
(Domus Medica). Processed by the Norwegian Food Safety
Authority (NFSA), 28.06. 2017.
Imaging was conducted in female Sprague Dawley rats
(13�1 months of age, 379�23 g, n=4). The animals were
anesthetised during the procedure, body temperature was
monitored using a rectal probe and maintained at 37 °C.
Anaesthesia was initialised with 5% isoflurane in air which was
reduced to 2% isoflurane for maintenance. The tail vein was
catheterised, and a saline plug was used to ensure that the
catheter was placed correctly and probes to record the
respiration and heart rate were connected accordingly. The
tracer (21�4 MBq, in 0.5�0.1 mL) was injected through the
catheter as slow bolus injection, For baseline scans, rats were
imaged at a dose of 2 nmol/kg, for blocking studies, animals
were pretreated with relugolix (3.5 μmol/kg) prior to injection
of 4 nmol/kg of the radiotracer. Each animal was scanned for
60 minutes. More information about the scanning protocol can
be found in the supporting information. Animals for harvesting
were not scanned and euthanised after 45 minutes. After re-test
of [18F]4, blood samples were taken from two further animals
(ID=38�3MBq) for 45 minutes and worked up for determina-
tion of radioactive metabolites. In brief, a blood sample (100μL)
was centrifuged at 5000 rpm (Eppendorf MiniSpin plus centri-
fuge) for 5 minutes. 50 μL of supernatant was taken and
transferred into a secondary Eppendorf vial containing meth-
anol. The Eppendorf vial was centrifuged for further 5 minutes.
The supernatant was injected directly into the analytic HPLC
Table 1. Binding affinity to rat GnRH receptors as determined from
competitive binding studies against [125I]buserelin.








1626ChemMedChem 2020, 15, 1624–1628 www.chemmedchem.org © 2020 The Authors. Published by Wiley-VCH GmbH
Wiley VCH Freitag, 21.08.2020


























































and spotted on TLC to separate blood metabolites from intact
radiotracer. Brain was harvested right after euthanising at
45 min p.i. and homogenised by grinding in methanol in a glass
tissue homogeniser for 5 minutes. After standing for few
minutes, 500 μL from the top layer was transferred into an
Eppendorf vial and centrifuged for 5 minutes. This supernatant
was injected into analytical HPLC and spotted on TLC to check
for brain metabolites. HPLC was evaluated by collection of the
eluate in fractions and counting in a NaI well counter. No intact
[18F]3 was found in the plasma supernatant; however, all
residual activity in blood was located in the precipitated protein
pellet which could be explained by near quantitative protein
binding of [18F]3 or by its inherently low solubility of 2 μg/mL at
pH 7.4. Unfortunately, activity in brain 60 min p.i. did not suffice
for detection or identification of the radiometabolites of
compound [18F]3 as the residual count rate was below the limit
of quantification. For compound [18F]4, more than 95% of the
residual activity in blood were intact radiotracer, only [18F]4 was
detected in brain with a corresponding distribution volume of
1.05.[22]
Other studies of GnRH  R antagonist have shown low brain
penetration.[14] However, in our study both tracers enter the
brain in a tenfold higher concentration as shown in Figure 1.
Whereas [18F]3 washes out quickly and shows negligible effect
of blocking, [18F]4 shows a steady accumulation in brain, albeit
at a slow rate after an initial peak. In order to confirm
displaceable binding in brain, animals (n=2) were pretreated
with relugolix to reduce availability of the GnRH  R. Relugolix
was given as a single dose 10 minutes prior to administration of
the radiotracer and animals were scanned for 60 minutes.
Although the receptor-saturating dose only marginally reduced
[18F]3 binding in GnRH rich regions, uptake increased in regions
with low GnRH expression at higher concentrations (up to 10%
in thalamus), possibly due to saturation of peripheral sites or
active transport of the tracer out of the brain, a clear effect of
the pretreatment was observed for [18F]4 ([18F]3:   28%; [18F]4:
  80% of specific binding); this is the first time such an effect
has been observed for GnRH radiotracers in the brain. Given
that the radiotracer was employed at a rather mediocre molar
activity, the pronounced mass dependency of the binding
might have resulted in a reduction of the specific even under
the baseline conditions. One may surmise that a somewhat
better performance could be expected when using a radiotracer
with a higher molar activity than [18F]4 in the present study.
Although the indication of some blockable uptake is a major
success, we suspect that the high molar mass of [18F]4 is a key
factor leading to the slow kinetics with increasing uptake over
60 minutes p.i.[23] On the other hand, the low nanomolar affinity
of 3 does seem to lead to saturable, detectable binding, it does
not seem high enough yet for successful imaging of GnRH
containing brain regions.
In conclusion, we have developed and tested two new
radiotracer candidates for PET imaging of GnRH  R in brain. One
of the candidates, compound [18F]4, shows for the first time
brain penetration and displaceable accumulation at GnRH  R
specific sites in the brain. Additionally, [18F]4 is a promising lead
structure for further developmental work targeting higher
binding affinity paired with a somewhat lower molar mass.
Conflict of Interest
The authors declare no conflict of interest.
Keywords: elagolix · fluorine-18 · GnRH  R · GnRH · PET
[1] J. B. Engel, A. V. Schally , Nat. Clin. Pract. Endocrinol. Metab. 2007, 3,
157–167.
[2] H. Van Poppel, S. Nilsson, Urology 2008, 71, 1001–1006.
[3] R. L. Gustofson, J. H. Segars, F. W. Larsen, Hum. Reprod. 2006, 21, 2830–
2837.
[4] S. Meethal, M. Smith, R. Bowen, C. Atwood, Endocrine 2005, 3, 317–325.
[5] A. Aguilar-Rojas, M. Huerta-Reyes, Oncol. Rep. 2009, 5, 981–990.
[6] L. W. Cheung, A. S. Wong, FEBS J. 2008, 22, 5479–5496.
[7] D. C. Skinner, A. J. Albertson, A. Navaratil, A. Smith, M. Mignot, H.
Talbott, N. Scanlan-Blake, J. Neuroendocrinol. 2009, 4, 282–292.
[8] J. L. Quintranar, E. Salinas, Neurochem. Res. 2008, 33, 1051–1056.
[9] G. Zhang, J. Li, S. Purkayastha, Y. Tang, H. Zhang, Y. Yin, B. Li, G. Liu, D.
Cai, Nature 2013, 497, 211–216.
[10] P. Brilken, A. Hill, W. Berner, J. Clin. Psychiatry 2003, 8, 890–897.
Figure 1. On the left side: Time activity curves for compounds [18F]3 and [18F]4 in the hippocampus (HIP) brain region of interest for representative animal





1627ChemMedChem 2020, 15, 1624–1628 www.chemmedchem.org © 2020 The Authors. Published by Wiley-VCH GmbH
Wiley VCH Freitag, 21.08.2020


























































[11] C. Eisenegger, M. Naef, R. Snozzi, M. Heinrichs, E. Fehr, Nature 2010, 463,
356–359.
[12] K Virdee, P. Cumming, D. Carpioli, B. Jupp, A. Rominger, F. I. Aigbirhio,
T. D. Fryer, P. J. Riss, J. W. Dalley, Neuroscience and Biobehavioural
Reviews 2012, 36, 1188–1216.
[13] D. E. Olberg, N. Bauer, K. W. Andressen, T. Hjørnevik, P. Cummings, F. O.
Levy, J. Klaveness, I. Haraldsen, J. L. Sutcliffe, Nucl. Med. Biol. 2016. 43,
478–489.
[14] D. E. Olberg, K. W. Andressen, F. O. Levy, J. Klaveness, I. Haraldsen, J. L.
Sutcliffe, Bioorg. Med. Chem. Lett. 2014, 24, 1846–1850.
[15] C. Chen, D. Wu, Z. Guo, Q. Xie, G. J. Reinhart, A. Madan, J. Wen, T. Chen,
C. Q. Huang, M. Chen, Y. Chen, F. C. Tucci, M. Rowbottom, J. Pontillo, Y.
Zhu, W. Wade, J. Saunders, H. Bozigian, R. S. Struthers, J. Med. Chem.
2008, 51, 7478–7485.
[16] R. Fjellaksel, M. Boomgaren, R. Sundset, I. H. Haraldsen, J. H. Hansen,
P. J. Riss, MedChemComm 2017, 8, 1965–1969.
[17] F. L. Tukun, D. E. Olberg, P. J. Riss, I. H. Haraldsen, A. Kaass, J. Klaveness,
Molecules 2017, 12, 2188.
[18] R. Fjellaksel, A. Moldes-Anaya, T. Vasskog, A. Oteiza, M. Martin-Armas,
O. K. Hjelstuen, J. H. Hansen, P. J. Riss, R. Sundset, J. Labelled Compd.
Radiopharm. 2019, 63, 72–84.
[19] T. A. Bramley, C. A. McPhie, G. S. Menzies, Placenta 1992, 13, 555–581.
[20] G. S. Menzies, T. A. Bramley, Placenta 1992, 13, 583–595.
[21] Y. Cheng, W. H. Prusoff, Biochem. Pharmacol. 1973, 23, 3099–3108.
[22] P. J. Riss, Y. T. Hong, J. Marton, D. Caprioli, D. J. Williamson, V. Ferrari, N.
Saigal, B. L. Roth, G. Henriksen, T. D. Fryer, J. W. Dalley, F. I. Aigbirhio, J.
Nuclear Med. 2013, 54, 299–305.
[23] M. Kuna, F. Mahdi, A. R. Chade, G. L. Bidwell III, Sci. Rep. 2018. 8, 7923.
Manuscript received: April 21, 2020
Revised manuscript received: July 12, 2020
Accepted manuscript online: July 16, 2020




1628ChemMedChem 2020, 15, 1624–1628 www.chemmedchem.org © 2020 The Authors. Published by Wiley-VCH GmbH
Wiley VCH Freitag, 21.08.2020
2017 / 173464 [S. 1628/1628] 1
